{
  "ticker": "OSX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02970870",
  "id": "02970870",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250721",
  "time": "0832",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250721/pdf/06lz6bnp1q7hj8.pdf",
  "summary": "### Summary of Material Information:  \n- **Clinical Trial Approval**: Osteopore's maxillomandibular reconstruction study at Princess Alexandra Hospital has received Research Governance Office (RGO) clearance.  \n- **Trial Timeline**: First patient recruitment expected in 4 weeks (~mid-August 2025); targets 10+ adult patients by 2028.  \n- **Technology**: Evaluates safety of Osteopore\u2019s PCL-TCP scaffold combined with vascularised tissue transfer for jawbone regeneration.  \n\n**Type**: Regulatory/clinical milestone (no immediate trading impact).  \n**Valuation Relevance**: Progress in regenerative medicine pipeline; potential long-term revenue driver if successful.  \n\n*No capital markets action or financial data disclosed.*",
  "usage": {
    "prompt_tokens": 1420,
    "completion_tokens": 150,
    "total_tokens": 1570,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-20T22:42:15.353498"
}